Personalis
PSNL
16.00
-0.03
-0.19%
Personalis
US · PSNL
#2890 by market cap
Listed 2019
16.00
-0.03
-0.19%
Live - 5344 symbols - heartbeat 309s ago
· 2026-10-08 04:13
Pre-market
16.07
+0.46%
After-hours
15.90
-0.63%
- Market cap
- 1.71B
- P/E (TTM)i
- -14.68
- P/Bi
- 7.27
- EPSi
- -0.91
- Div yieldi
- 0.00%
- 52W posi
- 79%
Reader sentiment
Are you bullish or bearish on PSNL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.7 percentage points.
Institutional ownership
- Held by institutions
- 80.22% -1.70pp
- Institutions
- 181 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund42.71%
Public Company16.27%
VC/PE Fund11.88%
Hedge Fund5.83%
Private Company2.33%
Individual/Insider1.21%
Government Pension Fund0.61%
Insurance Company0.54%
Other18.58%
Top holders as of 2026-07-19
Tempus AI, Inc.
12.21% · 13.04M sh
ARK Investment Management LLC
7.74% · 8.27M sh
BlackRock
6.63% · 7.08M sh
Lightspeed Management Company, LLC
5.71% · 6.10M sh
Columbia Management Investment Advisers, LLC
5.70% · 6.09M sh
Deep Track Capital, LP
3.75% · 4.00M sh
abrdn plc
3.51% · 3.75M sh
Vanguard Capital Management, LLC
3.24% · 3.46M sh
Casdin Capital, LLC
2.39% · 2.55M sh
Kennedy Capital Management LLC
2.21% · 2.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Tempus AI, Inc. | -- | 12.21% |
| Aaron Tachibana | Chief Financial Officer | 0.18% |
| Richard Chen | Executive VP of R&D and Chief Medical Officer | 0.12% |
| Christopher Hall | Chief Executive Officer | 0.09% |
| Stephen Moore | General Counsel | 0.08% |
| Lonnie Shoff | Independent Director | 0.03% |
| Woodrow Myers | Independent Director | 0.02% |
| Olivia Bloom | Independent Director | 0.02% |
| Karin Eastham | Independent Chairperson | 0.01% |
| Arthur Bowman | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-17 | Richard Chen | Executive VP of R&D and Chief Medical Officer | Open Market Disposition | -3,998 | $16.22 |
| 2026-09-17 | Aaron Tachibana | Chief Financial Officer | Open Market Disposition | -2,931 | $16.22 |
| 2026-09-17 | Stephen Moore | General Counsel | Open Market Disposition | -2,068 | $16.22 |
| 2026-09-17 | Christopher Hall | Chief Executive Officer | Open Market Disposition | -7,459 | $16.22 |
| 2026-07-14 | Richard Chen | Executive VP of R&D and Chief Medical Officer | Derivative Exercise and Sale | -100,000 | $2.44–15.15 |
| 2026-07-08 | Christopher Hall | Chief Executive Officer | Derivative Exercise and Sale | -100,000 | $1.61–15.08 |
| 2026-06-28 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -4,982 | $5.32–14.00 |
| 2026-06-25 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -51,251 | $5.32–13.18 |
| 2026-06-25 | Christopher Hall | Chief Executive Officer | Derivative Exercise and Sale | -100,000 | $1.61–13.15 |
| 2026-06-03 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -40,000 | $9.16–12.01 |
| 2026-05-28 | Aaron Tachibana | Chief Financial Officer | Derivative Exercise and Sale | -38,799 | $9.16–11.58 |
| 2026-05-28 | Christopher Hall | Chief Executive Officer | Derivative Exercise and Sale | -100,000 | $1.61–11.02 |
| 2026-05-27 | Christopher Hall | Chief Executive Officer | Intent to Sell (Form 144) | -100,000 | $9.49 |
| 2026-05-11 | Kenneth Widder | Director | Other Acquisition | +6,250 | -- |
| 2026-05-11 | Kenneth Widder | Director | Other Derivative Acquisition | +37,500 | $6.04 |
| 2026-05-11 | Karin Eastham | Independent Chairperson | Other Acquisition | +6,250 | -- |
| 2026-05-11 | Karin Eastham | Independent Chairperson | Other Derivative Acquisition | +37,500 | $6.04 |
| 2026-05-11 | Arthur Bowman | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-11 | Arthur Bowman | Independent Director | Other Derivative Acquisition | +37,500 | $6.04 |
| 2026-05-11 | Woodrow Myers | Independent Director | Other Acquisition | +6,250 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:13:33 · For reference only, not investment advice and not tailored to your situation.